PMID- 35100586
OWN - NLM
STAT- MEDLINE
DCOM- 20220823
LR  - 20220924
IS  - 1421-9786 (Electronic)
IS  - 1015-9770 (Linking)
VI  - 51
IP  - 5
DP  - 2022
TI  - Effect of SGLT2 Inhibitors on Risk of Stroke in Diabetes: A Meta-Analysis.
PG  - 585-593
LID - 10.1159/000521782 [doi]
AB  - BACKGROUND: The effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on 
      reducing the risk of stroke in patients with type 2 diabetes mellitus (T2DM) 
      remains unclear. Thus, we conducted this systemic review and meta-analysis of all 
      relevant studies and trials to explore the role of SGLT2 inhibitors on the stroke 
      prevention. METHODS: The present study included articles published before October 
      2021 and searched in Web of Science, PubMed databases. We used STATA 12.0 
      software to compute hazard ratio (HR) and 95% confidence interval (CI). RESULTS: 
      Meta-analysis indicated that SGLT2 inhibitors showed no significant effects on 
      risk of stroke in diabetes in randomized controlled trials with a fixed effects 
      model (HR = 0.98; 95% CI: 0.88-1.09, I2 = 22.3%, p = 0.272). Compared to other 
      glucose-lowering drugs (oGLD) and insulin, SGLT2 inhibitors alone significantly 
      affected risk of stroke in diabetes in observational studies with a random 
      effects model (HR = 0.87; 95% CI: 0.80-0.95, I2 = 72.2%, p < 0.001). CONCLUSIONS: 
      In summary, this meta-analysis indicated that the use of SGLT2 inhibitors did not 
      decrease the risk of stroke. And for some T2DM patients with high-risk factor of 
      stroke, SGLT2 inhibitors therapy may be more suitable compared to some oGLD such 
      as dipeptidyl peptidase-4 inhibitors. The results of this meta-analysis are 
      necessary to be confirmed with further studies and clinical trials.
CI  - (c) 2022 S. Karger AG, Basel.
FAU - Zhang, Chunhui
AU  - Zhang C
AD  - School of Nursing and Health, Zhengzhou University, Zhengzhou, China.
FAU - Zhang, Xian
AU  - Zhang X
AD  - School of Nursing and Health, Zhengzhou University, Zhengzhou, China.
FAU - Wang, Peng
AU  - Wang P
AD  - School of Nursing and Health, Zhengzhou University, Zhengzhou, China.
FAU - Zhu, Qinghua
AU  - Zhu Q
AD  - School of Nursing and Health, Zhengzhou University, Zhengzhou, China.
FAU - Mei, Yongxia
AU  - Mei Y
AD  - School of Nursing and Health, Zhengzhou University, Zhengzhou, China.
FAU - Zhang, Zhenxiang
AU  - Zhang Z
AD  - School of Nursing and Health, Zhengzhou University, Zhengzhou, China.
FAU - Xu, Hui
AU  - Xu H
AD  - School of Nursing and Health, Zhengzhou University, Zhengzhou, China.
LA  - eng
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20220131
PL  - Switzerland
TA  - Cerebrovasc Dis
JT  - Cerebrovascular diseases (Basel, Switzerland)
JID - 9100851
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/complications/diagnosis/drug therapy
MH  - Glucose/therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects
MH  - Insulin
MH  - *Sodium-Glucose Transporter 2 Inhibitors/adverse effects
MH  - *Stroke/diagnosis/epidemiology/etiology
OTO - NOTNLM
OT  - Diabetes
OT  - Meta-analysis
OT  - Sodium-glucose cotransporter 2 inhibitors
OT  - Stroke
EDAT- 2022/02/01 06:00
MHDA- 2022/08/24 06:00
CRDT- 2022/01/31 20:04
PHST- 2021/11/18 00:00 [received]
PHST- 2021/12/18 00:00 [accepted]
PHST- 2022/02/01 06:00 [pubmed]
PHST- 2022/08/24 06:00 [medline]
PHST- 2022/01/31 20:04 [entrez]
AID - 000521782 [pii]
AID - 10.1159/000521782 [doi]
PST - ppublish
SO  - Cerebrovasc Dis. 2022;51(5):585-593. doi: 10.1159/000521782. Epub 2022 Jan 31.